c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Products of "c-Met/HGFR"
Sort by
Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H17FN6OPurity:99.24%Color and Shape:SolidMolecular weight:412.42Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H21Cl2FN6O2Purity:99.77%Color and Shape:SolidMolecular weight:503.36Ref: TM-T8825
2mg35.00€5mg49.00€10mg69.00€25mg115.00€50mg177.00€100mg283.00€200mg378.00€1mL*10mM (DMSO)56.00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.65Ref: TM-T3113
2mg39.00€5mg57.00€10mg79.00€25mg133.00€50mg207.00€100mg354.00€500mg848.00€1mL*10mM (DMSO)79.00€Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Formula:C34H29ClF2N6O5Purity:98%Color and Shape:SolidMolecular weight:675.08Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formula:C27H23FN4O4SPurity:99.39%Color and Shape:SolidMolecular weight:518.56Ref: TM-T13108
1mg50.00€5mg106.00€10mg158.00€25mg258.00€50mg379.00€100mg538.00€200mg733.00€1mL*10mM (DMSO)134.00€JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formula:C20H12F2N6Purity:98.84% - 99.52%Color and Shape:SolidMolecular weight:374.35Ref: TM-T15617
1mg63.00€2mg89.00€5mg137.00€10mg210.00€25mg424.00€50mg627.00€100mg893.00€500mg1,786.00€1mL*10mM (DMSO)153.00€Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Purity:SDS-PAGE:95% SEC-HPLC:97.51%Color and Shape:LiquidMolecular weight:145.2 kDaAltiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:98.98% - 99.39%Color and Shape:SolidMolecular weight:510.46BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFormula:C17H15N5Purity:98.98%Color and Shape:SolidMolecular weight:289.33Ref: TM-T7900
1mg50.00€5mg97.00€10mg170.00€25mg306.00€50mg444.00€100mg620.00€200mg835.00€1mL*10mM (DMSO)114.00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Formula:C23H18ClFN6OPurity:98.62% - 99.12%Color and Shape:SolidMolecular weight:448.89Telisotuzumab
CAS:Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Purity:SDS-PAGE:96.4%;SEC-HPLC:98.5%Color and Shape:LiquidMolecular weight:145.50 kDaTerevalefim
CAS:Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.Formula:C9H8N2SPurity:99.53%Color and Shape:SolidMolecular weight:176.24Ref: TM-T37596
1mg56.00€5mg119.00€10mg210.00€25mg369.00€50mg537.00€100mg750.00€500mg1,539.00€1mL*10mM (DMSO)119.00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Formula:C25H19ClF2N4O4Purity:100% - 99.89%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2699
1mg35.00€5mg79.00€10mg124.00€25mg217.00€50mg359.00€100mg533.00€500mg1,169.00€1mL*10mM (DMSO)92.00€Tyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Formula:C31H31FN6O5Purity:98%Color and Shape:SolidMolecular weight:586.61CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formula:C20H20FN7O2Purity:99.29%Color and Shape:SolidMolecular weight:409.42C-Met inhibitor D9
CAS:C-Met inhibitor D9 is a c-Met kinase inhibitor.Formula:C17H15N3O2Purity:97%Color and Shape:SolidMolecular weight:293.32BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Formula:C23H15ClF2N4O3Purity:98% - 99.69%Color and Shape:SolidMolecular weight:468.84Ref: TM-T2419
1mg42.00€2mg52.00€5mg88.00€10mg150.00€25mg296.00€50mg537.00€100mg772.00€1mL*10mM (DMSO)95.00€LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formula:C18H11F3N4OPurity:100%Color and Shape:SoildMolecular weight:356.3SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFormula:C32H40ClF2N6O13PPurity:98.07%Color and Shape:SolidMolecular weight:821.12Ref: TM-T5349
1mg38.00€2mg49.00€5mg79.00€10mg119.00€25mg210.00€50mg350.00€100mg522.00€1mL*10mM (DMSO)107.00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.Formula:C29H25FN4O5Purity:98.60%Color and Shape:SolidMolecular weight:528.53Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFormula:C26H29Cl4FN6O3Purity:98.73%Color and Shape:SolidMolecular weight:634.36Ref: TM-T22324
1mg66.00€2mg93.00€5mg144.00€10mg227.00€25mg464.00€50mg677.00€100mg938.00€1mL*10mM (DMSO)188.00€JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Formula:C19H13F2N7Purity:97.04% - 98.27%Color and Shape:SolidMolecular weight:377.35EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLCFormula:C32H23ClF3N7O4Purity:97.45%Color and Shape:SolidMolecular weight:662.02Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Formula:C31H28ClF2N5O3S2Purity:98%Color and Shape:SolidMolecular weight:656.16NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C25H22N8O5SPurity:98%Color and Shape:SolidMolecular weight:546.56Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Formula:C17H15N9Purity:98.12%Color and Shape:SolidMolecular weight:345.36Ref: TM-TQ0210
1mg49.00€2mg64.00€5mg92.00€10mg131.00€25mg210.00€50mg373.00€100mg567.00€1mL*10mM (DMSO)97.00€SAR125844
CAS:SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Formula:C25H23FN8O2S2Purity:98.39%Color and Shape:SolidMolecular weight:550.63Ref: TM-T5467
1mg35.00€5mg79.00€10mg116.00€25mg227.00€50mg364.00€100mg588.00€200mg833.00€1mL*10mM (DMSO)96.00€Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Formula:C32H33ClFN5O11Purity:100% - 98.11%Color and Shape:SolidMolecular weight:718.08Ref: TM-T1773
1g467.00€5mg40.00€10mg59.00€25mg87.00€50mg107.00€100mg140.00€200mg188.00€500mg313.00€1mL*10mM (DMSO)66.00€Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formula:C29H49N4O10PPurity:97.05%Color and Shape:SolidMolecular weight:644.69Ref: TM-T39507L
1mg116.00€2mg160.00€5mg238.00€10mg353.00€25mg563.00€50mg758.00€100mg1,017.00€200mg1,359.00€Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formula:C20H15F3N8Purity:99.16%Color and Shape:SolidMolecular weight:424.38Ref: TM-T10585
1mg97.00€5mg216.00€10mg354.00€25mg628.00€50mg905.00€100mg1,264.00€200mg1,700.00€1mL*10mM (DMSO)240.00€c-Met-IN-2
CAS:c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Formula:C24H21FN10OPurity:98%Color and Shape:SolidMolecular weight:484.49PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFormula:C15H14N2OPurity:96.09% - ≥95%Color and Shape:SolidMolecular weight:238.28Ref: TM-T2496
1mg57.00€5mg111.00€10mg188.00€25mg331.00€50mg568.00€100mg695.00€200mg948.00€1mL*10mM (DMSO)144.00€MK-2461
CAS:MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFormula:C24H25N5O5SPurity:95.41% - 99.53%Color and Shape:SolidMolecular weight:495.55Ref: TM-T6094
1mg52.00€5mg120.00€10mg187.00€25mg363.00€50mg552.00€100mg842.00€200mg1,130.00€1mL*10mM (DMSO)134.00€NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formula:C20H16N6Purity:100% - 98.61%Color and Shape:SolidMolecular weight:340.38Ref: TM-T2680
2mg44.00€5mg74.00€10mg97.00€25mg178.00€50mg255.00€100mg359.00€200mg510.00€1mL*10mM (DMSO)84.00€AMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Formula:C23H22FN7O3Purity:99.26% - 99.9%Color and Shape:SolidMolecular weight:463.46Ref: TM-T3209
1mg40.00€2mg52.00€5mg85.00€10mg124.00€25mg197.00€50mg350.00€100mg522.00€200mg748.00€1mL*10mM (DMSO)86.00€MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFormula:C29H29N7OPurity:98%Color and Shape:SolidMolecular weight:491.59c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37
